Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
5.766 JPY | -2,72% | -4,85% | +7,94% |
27/03 | Roche's Chugai krijgt Japanse goedkeuring voor Piasky-injectie | MT |
21/03 | Argenx flink in de lift | AM |
Vakgebied
De netto-omzet is geografisch als volgt verdeeld: Japan (74,3%), Zwitserland (22,8%) en overig (2,9%).
Aantal werknemers: 7 771
Verkoop per activiteit
JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceuticals
87,7
%
| 1 039 247 | 82,5 % | 974 493 | 87,7 % | -6,23% |
Other
12,3
%
| 91 915 | 7,3 % | 136 874 | 12,3 % | +48,91% |
Verkoop per regio
JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Japan
50,3
%
| 657 273 | 52,2 % | 559 233 | 50,3 % | -14,92% |
Switzerland
46,1
%
| 482 736 | 38,3 % | 511 880 | 46,1 % | +6,04% |
Overseas
3,6
%
| 119 936 | 9,5 % | 40 253 | 3,6 % | -66,44% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Osamu Okuda
CEO | Chief Executive Officer | 60 | 01-04-87 |
Junichi Nezu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Hisafumi Okabe
CTO | Chief Tech/Sci/R&D Officer | - | - |
Motoo Ueno
BRD | Director/Board Member | 66 | 01-04-84 |
Yoko Kitagawa
IRC | Investor Relations Contact | - | - |
Keiji Kono
IRO | Public Communications Contact | - | - |
Yoshiaki Ohhashi
PRN | Corporate Officer/Principal | - | - |
Yoshiyuki Yano
HRO | Human Resources Officer | - | - |
Shinji Hidaka
SAM | Sales & Marketing | - | - |
Atsushi Sato
AUD | Comptroller/Controller/Auditor | 65 | 01-04-81 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Masayuki Oku
BRD | Director/Board Member | 79 | 01-03-15 |
Motoo Ueno
BRD | Director/Board Member | 66 | 01-04-84 |
James H. Sabry
BRD | Director/Board Member | 65 | 01-03-19 |
Christoph Franz
BRD | Director/Board Member | 63 | 01-03-17 |
Director/Board Member | 75 | 01-03-17 | |
William Anderson
BRD | Director/Board Member | 57 | 01-03-19 |
Osamu Okuda
CEO | Chief Executive Officer | 60 | 01-04-87 |
Mariko Momoi
BRD | Director/Board Member | 76 | 01-03-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 1 679 057 667 | 639 373 741 ( 38,08 %) | 33 743 712 ( 2,010 %) | 38,08 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
33 788 400 | 2.01% | 1 354 515 799 $ | |
ONCOLYS BIOPHARMA INC. 2.25% | 456 600 | 2.25% | 1 781 617 $ |
Bedrijfsgegevens
Chugai Pharmaceutical Co., Ltd.
Nihonbashi Mitsui Tower, 15/F 2-1-1 Nihonbashi-Muromachi
103-8324, Tokyo
+81 3 3281 6611
http://www.chugai-pharm.co.jpSector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,94% | 64,42 mld. | |
+33,46% | 701 mld. | |
+26,24% | 571 mld. | |
+0,93% | 381 mld. | |
+21,03% | 334 mld. | |
+17,51% | 319 mld. | |
+0,74% | 210 mld. | |
+2,95% | 210 mld. | |
-6,05% | 201 mld. | |
-3,61% | 157 mld. |
- Beurs
- Aandelen
- Aandeel Chugai Pharmaceutical Co., Ltd - Japan Exchange
- Onderneming Chugai Pharmaceutical Co., Ltd